Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + vorinostat
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination therapy consisting of bevacizumab, a humanized monoclonal IgG1 antibody targeting vascular endothelial growth factor (VEGF), and vorinostat, a small molecule histone deacetylase (HDAC) inhibitor. Bevacizumab works by inhibiting angiogenesis through VEGF blockade, while vorinostat crosses the blood-brain barrier and has anti-tumor effects by inhibiting histone deacetylase and indirectly promoting anti-angiogenic activity. This combination represents a rational therapeutic approach that targets both endothelial cells to block angiogenesis and prevents tumor adaptation to the resulting hypoxia by downregulating angiogenesis-related gene expression.
- Brand names
- ZolinzaAvastin
- Other names
- Suberoylanilide hydroxamic acidvorinostat and bevacizumab combination
02
Targets
HDAC (HDAC family)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on bevacizumab + vorinostat.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + vorinostat.